lmat20221027_8k.htm
false 0001158895 0001158895 2022-10-27 2022-10-27
 


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  October 27, 2022
 
LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)
 
Commission File Number:  001-33092
 
Delaware
 
04-2825458
(State or other jurisdiction of
 
(IRS Employer
incorporation)
 
Identification No.)
 
63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)
 
781-221-2266
(Registrants telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12c-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
 
Title of each class
Trading symbol
Name of exchange on which registered
Common stock, $0.01 par value per share
LMAT 
The Nasdaq Global Market
 
 

 
Item 2.02. Results of Operations and Financial Condition.
 
On October 27, 2022, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Report.
 
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
 
Disclaimer on Forward-Looking Statements
 
This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
 
 
Item 9.01. Financial Statements and Exhibits.
 
The following exhibits are furnished or filed as part of this Report, as applicable:
 
 
(d)
Exhibits.
 
     
Exhibit No.
 
Description
     
99.1
 
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
 
Signature(s)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
   
LeMaitre Vascular, Inc.
                 
                 
Date: October 27, 2022
 
 
 
By:
 
Joseph P. Pellegrino, Jr.
/s/ JOSEPH P. PELLEGRINO, JR.
               
Joseph P. Pellegrino, Jr.
Chief Financial Officer
 
 

 
 
Exhibit Index
     
Exhibit No.
 
Description
     
99.1
 
Press release issued by LeMaitre Vascular, Inc. on October 27, 2022.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
ex_438244.htm

Exhibit 99.1

 

LeMaitre Q3 2022 Financial Results

 

BURLINGTON, MA, October 27, 2022 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2022 results, announced a $0.125/share quarterly dividend and provided guidance.

 

Q3 2022 Financial Results

 

 

Sales of $39.0mm, +2% (+7% organic) vs. Q3 2021

 

Op. income $6.2mm, -32%

 

Op. margin of 16%

 

Net income of $5.5mm, -16%

 

Earnings per diluted share $0.25, -17%

 

Cash and investments +$4.1mm to $79.7mm

 

Q3 2022 sales growth was driven by carotid shunts (+23%), Artegraft (+12%), allografts (+10%) and embolectomy catheters (+10%). By geography, organic sales increased 11% in APAC, 8% in EMEA and 6% in the Americas. The strong U.S. dollar reduced sales by $1.9mm.

 

The gross margin decreased to 64.2% in Q3 2022 (vs. 64.8% in Q3 2021). The strong dollar reduced the gross margin by 1.7% year-over-year. The Company had 213 direct labor employees as of September 30, up 54% year-over-year.

 

Q3 2022 operating income was $6.2mm. Q3 operating expense growth was driven by increased headcount, including a 28% larger salesforce (118 reps on September 30), as well as MDR-related regulatory expenses.

 

George LeMaitre, Chairman and CEO, said “In Q3 we grew 7% organically and increased our cash balance by $4.1 million to $79.7 million. We continue to build sales rep and direct labor headcount, both now at high-water marks. We expect these investments will drive organic sales growth and improvement to the gross margin in the quarters ahead.”

 

Business Outlook

 

 

 

Q4 2022 Guidance

 

2022 Full Year Guidance

Sales

$39.8mm - $42.2mm

(Mid: $41.0mm, +4%, +9% Org.)

$160.5mm - $162.9mm

(Mid:$161.7mm, +5%, +9% Org.)

Gross Margin

65.8% 65.4%

Op. Income

$6.6mm - $8.2mm

(Mid: $7.4mm, -11%)

$26.5mm - $28.0mm

(Mid $27.2mm, -25%)

Op. Income Ex-

Spec. Charge

-

$29.6mm - $31.1mm

(Mid: $30.3mm, -17%)

EPS

$0.24 - $0.29

(Mid: $0.26, -5%)

$0.91 - $0.97

(Mid: $0.94, -25%)

EPS Ex-

Spec. Charge

-

$1.02 - $1.08

(Mid: $1.05, -16%)

 

Quarterly Dividend

 

On October 25, 2022, the Company's Board of Directors approved a quarterly dividend of $0.125/share of common stock. The dividend will be paid on December 1, 2022 to shareholders of record on November 17, 2022.

 

Share Repurchase Program

 

On February 22, 2022, the Company's Board of Directors authorized the repurchase of up to $20.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 22, 2023, unless extended by the Board.

 

Board Appointment

 

On September 21, 2022, the Company’s Board of Directors appointed Martha Shadan as an independent director. Ms. Shadan has over 20 years of life sciences experience, including President and CEO at Miach Orthopedics and Rotation Medical. Ms. Shadan currently serves on the boards of CVRx and AdvaMed.

 

 

 

Conference Call Reminder

 

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at http://www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company's website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

 

About LeMaitre

 

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

 

For more information about the Company, please visit http://www.lemaitre.com.

 

Use of Non-GAAP Financial Measures

 

LeMaitre management believes that in order to better understand the Company's short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

 

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events as well as EBITDA or earnings before interest, taxes, depreciation and amortization and guidance for full year operating income and EPS excluding special charge. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and the aforementioned non-GAAP profitability measures to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that evaluating EBITDA provides an approximation of the cash generating ability of its operations. The Company believes that the presentation of full year guidance for operating income and EPS excluding special charge provides an alternative and meaningful view of the Company’s profitability excluding the impact of the closure of the Company’s St. Etienne, France factory, a non-recurring event.

 

Forward-Looking Statements

 

The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the status of our global regulatory approvals and compliance with regulatory requirements to market and sell our products both in the U.S. and outside of the U.S.; the duration and severity of the impact of COVID-19 on the global economy, our customers, our suppliers and our company; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; the risk that we may not be able to maintain our recent levels of profitability; the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the acceleration or deceleration of product growth rates; risks related to product demand and market acceptance of the Company’s products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

 

CONTACT: 

J.J. Pellegrino, CFO, LeMaitre
781-425-1691
jjpellegrino@lemaitre.com

 

 

 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

               

CONDENSED CONSOLIDATED BALANCE SHEETS

               

(amounts in thousands)

               
                 
                 
   

September 30, 2022

   

December 31, 2021

 
   

(unaudited)

         

Assets

               
                 

Current assets:

               

Cash and cash equivalents

  $ 16,913     $ 13,855  

Short-term marketable securities

    62,826       56,104  

Accounts receivable, net

    20,094       19,631  

Inventory and other deferred costs

    47,711       46,104  

Prepaid expenses and other current assets

    4,842       4,189  

Asset held for sale

    756       -  

Total current assets

    153,142       139,883  
                 

Property and equipment, net

    15,351       17,059  

Right-of-use leased assets

    15,785       15,071  

Goodwill

    65,945       65,945  

Other intangibles, net

    48,063       52,710  

Deferred tax assets

    2,789       1,566  

Other assets

    973       568  
                 

Total assets

  $ 302,048     $ 292,802  
                 
                 

Liabilities and stockholders' equity

               
                 

Current liabilities:

               

Accounts payable

  $ 2,848     $ 2,340  

Accrued expenses

    17,400       16,332  

Acquisition-related obligations

    1,363       1,271  

Lease liabilities - short-term

    1,828       1,870  

Total current liabilities

    23,439       21,813  
                 

Lease liabilities - long-term

    14,897       14,067  

Deferred tax liabilities

    60       70  

Other long-term liabilities

    2,405       2,701  

Total liabilities

    40,801       38,651  
                 

Stockholders' equity

               

Common stock

    236       235  

Additional paid-in capital

    186,798       181,630  

Retained earnings

    94,896       88,125  

Accumulated other comprehensive loss

    (8,127 )     (3,435 )

Treasury stock

    (12,556 )     (12,404 )

Total stockholders' equity

    261,247       254,151  
                 

Total liabilities and stockholders' equity

  $ 302,048     $ 292,802  

 

 

 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

                         

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

                         

(amounts in thousands, except per share amounts)

                               

(unaudited)

                               
                                 
   

For the three months ended

   

For the nine months ended

 
   

September 30, 2022

   

September 30, 2021

   

September 30, 2022

   

September 30, 2021

 
                                 

Net sales

  $ 39,028     $ 38,368     $ 120,697     $ 114,921  

Cost of sales

    13,958       13,502       41,855       39,495  
                                 

Gross profit

    25,070       24,866       78,842       75,426  
                                 

Operating expenses:

                               

Sales and marketing

    8,229       6,941       24,321       20,210  

General and administrative

    7,229       6,004       21,812       18,748  

Research and development

    3,462       2,848       9,740       8,344  

Restructuring

    -       -       3,107       -  

Total operating expenses

    18,920       15,793       58,980       47,302  
                                 

Income from operations

    6,150       9,073       19,862       28,124  
                                 

Other income (expense), net

                               

Interest income

    264       54       539       56  

Interest expense

    -       (621 )     -       (1,693 )

Foreign currency gain (loss)

    (266 )     (72 )     (709 )     (105 )
                                 

Income before income taxes

    6,148       8,434       19,692       26,382  
                                 

Provision for income taxes

    692       1,930       4,683       5,650  
                                 

Net income

  $ 5,456     $ 6,504     $ 15,009     $ 20,732  
                                 

Earnings per share of common stock

                               

Basic

  $ 0.25     $ 0.30     $ 0.68     $ 0.99  

Diluted

  $ 0.25     $ 0.30     $ 0.68     $ 0.98  
                                 

Weighted - average shares outstanding:

                               

Basic

    21,984       21,592       21,959       20,920  

Diluted

    22,217       21,935       22,149       21,251  
                                 
                                 

Cash dividends declared per common share

  $ 0.125     $ 0.110     $ 0.375     $ 0.330  

 

 

 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

SELECTED NET SALES INFORMATION

(amounts in thousands)

(unaudited)

 

 

   

For the three months ended

   

For the nine months ended

 
   

September 30, 2022

   

September 30, 2021

   

September 30, 2022

   

September 30, 2021

 
    $    

%

    $    

%

    $    

%

    $    

%

 

Net Sales by Geography

                                                               

Americas

  $ 26,627       68 %   $ 25,299       66 %   $ 82,024       68 %   $ 76,327       67 %

Europe, Middle East and Africa

    9,922       25 %     10,535       27 %     31,165       26 %     31,200       27 %

Asia Pacific

    2,479       7 %     2,534       7 %     7,508       6 %     7,394       6 %

Total Net Sales

  $ 39,028       100 %   $ 38,368       100 %   $ 120,697       100 %   $ 114,921       100 %

 

 

 

 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

                       

NON-GAAP FINANCIAL MEASURES

                       

(amounts in thousands)

                       

(unaudited)

                       
                         
                         

Reconciliation between GAAP and Non-GAAP sales growth:

                       

For the three months ended September 30, 2022

                       

Net sales as reported

  $ 39,028                  

Impact of currency exchange rate fluctuations

    1,895                  

Adjusted net sales

          $ 40,923          
                         

For the three months ended September 30, 2021

                       

Net sales as reported

  $ 38,368                  

Adjusted net sales

          $ 38,368          
                         

Adjusted net sales increase for the three months ended September 30, 2022

          $ 2,555       7 %
                         
                         

APAC sales growth reconciliation between GAAP and Non-GAAP:

                       

For the three months ended September 30, 2022

                       

Net sales as reported

  $ 2,479                  

Impact of currency exchange rate fluctuations

    334                  

APAC adjusted net sales

          $ 2,813          
                         

For the three months ended September 30, 2021

                       

Net sales as reported

  $ 2,534                  

Adjusted net sales

          $ 2,534          
                         

APAC adjusted net sales increase for the three months ended September 30, 2022

    $ 279       11 %
                         
                         

EMEA sales growth reconciliation between GAAP and Non-GAAP:

                       

For the three months ended September 30, 2022

                       

Net sales as reported

  $ 9,922                  

Impact of currency exchange rate fluctuations

    1,486                  

EMEA adjusted net sales

          $ 11,408          
                         

For the three months ended September 30, 2021

                       

Net sales as reported

  $ 10,535                  

Adjusted net sales

          $ 10,535          
                         

EMEA adjusted net sales increase for the three months ended September 30, 2022

    $ 873       8 %
                         
                         

Americas sales growth reconciliation between GAAP and Non-GAAP:

                       

For the three months ended September 30, 2022

                       

Net sales as reported

  $ 26,627                  

Impact of currency exchange rate fluctuations

    74                  

Americas adjusted net sales

          $ 26,701          
                         

For the three months ended September 30, 2021

                       

Net sales as reported

  $ 25,299                  

Adjusted net sales

          $ 25,299          
                         

Americas adjusted net sales increase for the three months ended September 30, 2022

    $ 1,402       6 %

 

 

 

 

Reconciliation between GAAP and Non-GAAP projected sales growth:

                       

For the three months ending December 31, 2022

                       

Net sales per guidance (midpoint)

  $ 41,000                  

Impact of currency exchange rate fluctuations

    2,049                  

Adjusted projected net sales

          $ 43,049          
                         

For the three months ended December 31, 2021

                       

Net sales as reported

  $ 39,503                  

Adjusted net sales

          $ 39,503          
                         

Adjusted projected net sales increase for the three months ending December 31, 2022

    $ 3,546       9 %
                         
                         

Reconciliation between GAAP and Non-GAAP projected sales growth:

                       

For the year ending December 31, 2022

                       

Net sales per guidance (midpoint)

  $ 161,697                  

Impact of currency exchange rate fluctuations

    6,445                  

Adjusted projected net sales

          $ 168,142          
                         

For the year ended December 31, 2021

                       

Net sales as reported

  $ 154,424                  

Adjusted net sales

          $ 154,424          
                         

Adjusted projected net sales increase for the year ending December 31, 2022

    $ 13,718       9 %
                         
                         

Reconciliation between GAAP and Non-GAAP projected operating income:

                       

For the year ending December 31, 2022

                       

Operating income per guidance (midpoint)

  $ 27,242                  

Impact of special charge

    3,107                  

Adjusted projected operating income

          $ 30,349          
                         

For the year ended December 31, 2021

                       

Operating income as reported

  $ 36,425                  

Adjusted operating income

          $ 36,425          
                         

Adjusted projected operating income decrease for the year ending December 31, 2022

    $ (6,076 )     -17 %
                         
                         

Reconciliation between GAAP and Non-GAAP projected EPS:

                       

For the year ending December 31, 2022

                       

EPS per guidance (midpoint)

  $ 0.94                  

Impact of special charge

  $ 0.11                  

Adjusted EPS

          $ 1.05          
                         

For the year ended December 31, 2021

                       

EPS as reported

  $ 1.25                  

Adjusted EPS

          $ 1.25          
                         

Adjusted projected EPS decrease for the year ending December 31, 2022

          $ (0.20 )     -16 %

 

 

 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

 

 

   

For the three months ended

   

For the nine months ended

   

LTM

 
   

September 30, 2022

   

September 30, 2022

   

September 30, 2022

 

Reconciliation between GAAP and Non-GAAP EBITDA

                       

Net income as reported

  $ 5,456     $ 15,009     $ 21,184  

Interest (income) expense, net

    (264 )     (539 )     (154 )

Amortization and depreciation expense

    2,328       7,145       9,504  

Provision for income taxes

    692       4,683       6,413  
                         

EBITDA

  $ 8,212     $ 26,298     $ 36,947